BCL2 and neoplasm: Overall, inhibitors/degraders of the BCL-2 family kill cancer cells directly, which can further sensitize cancer cells to other therapeutics or can produce tumor antigens for activation of the tumor-immune cycle via DC-mediated antigen presentation.